Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele


ABSTRACT

BACKGROUND
Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, and nearly 90% of patients have at least one copy of the Phe508del CFTR mutation. In a phase 2 trial involving patients who were heterozygous for the Phe508del CFTR mutation and a minimal-function mutation (Phe508del–minimal function genotype), the next-generation CFTR corrector elexacaftor, in combination with tezacaftor and ivacaftor, improved Phe508del CFTR function and clinical outcomes.

METHODS
We conducted a phase 3, randomized, double-blind, placebo-controlled trial to confirm the efficacy and safety of elexacaftor–tezacaftor–ivacaftor in patients 12 years of age or older with cystic fibrosis with Phe508del–minimal function genotypes. Patients were randomly assigned to receive elexacaftor–tezacaftor–ivacaftor or placebo for 24 weeks. The primary end point was absolute change from baseline in percentage of predicted forced expiratory volume in 1 second (FEV₁) at week 4.

RESULTS
A total of 403 patients underwent randomization and received at least one dose of active treatment or placebo. Elexacaftor–tezacaftor–ivacaftor, relative to placebo, resulted in a percentage of predicted FEV₁ that was 13.8 points higher at 4 weeks and 14.3 points higher through 24 weeks, a rate of pulmonary exacerbations that was 63% lower, a respiratory domain score on the Cystic Fibrosis Questionnaire–Revised (range, 0 to 100, with higher scores indicating a higher patient-reported quality of life with regard to respiratory symptoms; minimum clinically important difference, 4 points) that was 20.2 points higher, and a sweat chloride concentration that was 41.8 mmol per liter lower (P<0.001 for all comparisons). Elexacaftor–tezacaftor–ivacaftor was generally safe and had an acceptable side-effect profile. Most patients had adverse events that were mild or moderate. Adverse events leading to discontinuation of the trial regimen occurred in 1% of the patients in the elexacaftor–tezacaftor–ivacaftor group.

CONCLUSIONS
Elexacaftor–tezacaftor–ivacaftor was efficacious in patients with cystic fibrosis with Phe508del–minimal function genotypes, in whom previous CFTR modulator regimens were ineffective. (Funded by Vertex Pharmaceuticals; VX17-445-102 ClinicalTrials.gov number, NCT03525444.)
Cystic Fibrosis Is a Lethal, Inherited, Autosomal Recurrent Disorder That Affects Apparently 80,000 People Worldwide and Is Caused by Mutations in the Gene Encoding the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein That Lead to Reduced CFTR Function.1-3 CFTR codes for an epithelial anion channel that transports both Cl– and HCO3– across epithelial surfaces in the respiratory tract, pancreas, gastrointestinal system, and sweat glands, among other organs.1,2,4,5 Although there are hundreds of different disease-causing mutations, nearly 90% of people with cystic fibrosis have at least one copy of the most common mutation, the Phe508del CFTR mutation.6

The Phe508del CFTR mutation causes defective intracellular processing and trafficking and decreased stability, which drastically reduces the quantity of CFTR protein at the apical surface of epithelial cells.4,5,7 Phe508del CFTR protein also exhibits defective channel gating, which further limits anion transport.7 To restore Phe508del CFTR function, these molecular defects need to be addressed.

CFTR modulators treat the underlying cause of disease and have improved clinical outcomes in people with specific CFTR mutations.8-12 These medications include small-molecule correctors that increase cell-surface expression by improving the processing and trafficking of CFTR, as well as small-molecule potentiators that augment channel gating.13 For people with cystic fibrosis who are homozygous for the Phe508del CFTR mutation, the combination of a single corrector, either lumacaftor or tezacaftor, with the potentiator ivacaftor improves clinical outcomes, including lung function and the rate of pulmonary exacerbations.9,11 However, neither of these dual combinations is sufficiently effective in people with cystic fibrosis who have a single Phe508del allele and a second CFTR mutation that does not respond to current CFTR modulator therapy.14,15 Such mutations are termed “minimal function” because of the complete absence of protein production or lack of in vitro responsiveness to ivacaftor and tezacaftor–ivacaftor.16,17 For these patients, no treatment is available to treat the underlying cause of disease.

We studied the effect of a triple-combination CFTR modulator regimen in patients with cystic fibrosis who have a single Phe508del allele. The combination includes the next-generation corrector elixacaftor plus the corrector tezacaftor and the potentiator ivacaftor to more fully restore the function of Phe508del CFTR.18 In proof-of-concept trials that evaluated this therapeutic approach,16,18 elixacaftor–tezacaftor–ivacaftor led to improvements in spirometry, patient-reported respiratory symptoms, and sweat chloride concentration, a marker of CFTR activity, in patients with cystic fibrosis with a single Phe508del allele.18 To confirm efficacy and safety in this population, we conducted a randomized, placebo-controlled, phase 3 trial (VX17-445-102) of elixacaftor–tezacaftor–ivacaftor in patients who were heterozygous for the Phe508del CFTR mutation and a minimal-function mutation (Phe508del–minimal function genotypes).
intervention period could enroll in an ongoing 96-week open-label extension study in which all patients receive active treatment (VX17-445-105; ClinicalTrials.gov number, NCT03525574).

The trial was designed by Vertex Pharmaceuticals in collaboration with the authors. Data gathering and analysis were performed by Vertex Pharmaceuticals in collaboration with the authors and the VX17-445-102 Study Group. The clinical trial protocol and informed-consent forms were approved by an independent ethics committee at each site. Each enrolled patient, or the patient’s legal guardian, provided written informed consent (and assent, when appropriate). Safety was monitored by an independent data monitoring committee. All authors had full access to the trial data after final database lock and critically reviewed the manuscript. The first two authors and last two authors wrote the first draft of the manuscript and made final decisions regarding the content of the submitted manuscript. All authors approved the manuscript for submission. The investigators vouch for the accuracy and completeness of the data generated at their respective sites, and the investigators and Vertex Pharmaceuticals vouch for the fidelity of the trial to the protocol. Confidentiality agreements were in place between the sponsor and each investigative site during the trial.

END POINTS
The primary end point was absolute change from baseline in percentage of predicted FEV₁ at week 4. Key secondary end points were absolute change from baseline in percentage of predicted FEV₁ through week 24, number of pulmonary exacerbations through week 24, absolute change from baseline in sweat chloride concentration through week 24, absolute change from baseline in the Cystic Fibrosis Questionnaire–Revised (CFQ-R) respiratory domain score (range, 0 to 100, with higher scores indicating a higher patient-reported quality of life with regard to respiratory symptoms; minimum clinically important difference, 4 points) through week 24, absolute change from baseline in body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) at week 24, absolute change from baseline in sweat chloride concentration at week 4, and absolute change from baseline in the CFQ-R respiratory domain score at week 4. Other secondary end points included time to first pulmonary exacerbation through week 24, absolute change from baseline in BMI-for-age z score at week 24, absolute change from baseline in body weight at week 24, and safety and side-effect profile.

STATISTICAL ANALYSIS
Efficacy analyses included all patients who underwent randomization and received at least one dose of elexacaftor–tezacaftor–ivacaftor or placebo. The absolute change from baseline in percentage of predicted FEV₁ at week 4 was analyzed with the use of a mixed-effects model for repeated measures, with change from baseline in percentage of predicted FEV₁ as the dependent variable. The model included trial group, visit, and trial-group–by–visit interaction as fixed effects, with continuous baseline percentage of predicted FEV₁, age at screening (<18 years vs. ≥18 years), and sex as covariates; the model used an unstructured covariance for the within-patient errors. A similar mixed-effects model for repeated measures was applied to analyses of the key secondary end points of percentage of predicted FEV₁ through week 24, sweat chloride concentration, CFQ-R respiratory domain score, and BMI. The number of pulmonary exacerbations was analyzed with the use of a negative binomial-regression model.

A prespecified interim analysis was conducted for the primary end point when at least 140 patients had completed the week 4 visit and at least 100 patients had completed the week 12 visit. A Lan–DeMets alpha-spending function was applied to control the overall type I error rate of 0.05 for the primary end point. Assuming a 5% dropout rate at week 4 and a within-group standard deviation of 7 percentage points, we estimated that an interim-analysis sample size of 70 patients per trial group would provide approximately 98% power to detect a between-group difference of 5.0 points for the mean absolute change from baseline in percentage of predicted FEV₁ at week 4, using a two-sided, two-sample t-test at a significance level of 0.044 based on the alpha-spending function. Safety analyses were descriptive and included all patients who received at least one dose of elexacaftor–tezacaftor–ivacaftor or placebo.
**RESULTS**

**POPULATION**

The trial was conducted at 115 sites in 13 countries from June 2018 to April 2019. Overall, 405 patients underwent randomization, and 403 received at least one dose of the trial regimen (200 in the elexacaftor–tezacaftor–ivacaftor group and 203 in the placebo group) (Fig. S2). At baseline, the trial groups were well matched (Table 1 and Table S2). The mean adherence to the trial regimen was more than 98% in both trial groups. All 400 patients who completed the intervention period were enrolled in the open-label extension study.

**EFFICACY**

Treatment with elexacaftor–tezacaftor–ivacaftor resulted in significant improvement in the primary end point of absolute change in percentage of predicted FEV₁ at week 4, assessed at the interim analysis, with a mean treatment difference of 13.8 points relative to placebo (P<0.001) (Table 2 and Fig. 1A). Sustained improvement in percentage of predicted FEV₁ was seen through week 24 (final analysis), with a mean treatment difference of 14.3 points relative to placebo (P<0.001) (Table 2 and Fig. 1A). The histogram of absolute change in percentage of predicted FEV₁ through week 24 showed marked separation of the two trial groups (Fig. 1B).

Subgroup analysis for absolute change in percentage of predicted FEV₁ at week 4 showed that the mean treatment difference was consistent across all prespecified subgroups (Fig. S3). This difference was also consistent in the subgroup of patients in whom the minimal-function mutation caused an absence of CFTR protein production (78.0% of the trial population) and those with missense or in-frame deletion mutations (Table S3). Patients with a percentage of predicted FEV₁ of less than 40% at baseline (8.4% of the trial population) had a similar magnitude change in percentage of predicted FEV₁ at week 4 as the overall population (Table S4).

Sweat chloride concentrations improved significantly through week 24, with a mean treatment difference of −41.8 mmol per liter relative to placebo (0.37; 95% confidence interval, 0.25 to 0.55; P<0.001) (Table 2). A similar benefit was seen with respect to the rate of exacerbations that led to hospitalization or that were treated with intravenous antibiotics (Fig. 1C). A higher percentage of patients in the elexacaftor–tezacaftor–ivacaftor group than in the placebo group remained free of pulmonary exacerbations (Fig. S4).

Sweat chloride concentrations improved significantly through week 24, with a mean treatment difference of −41.8 mmol per liter relative to placebo (P<0.001) (Table 2 and Fig. 2A). The histogram of absolute change in sweat chloride concentration through week 24 showed separation of the two groups (Fig. 2B). The mean sweat chloride concentration in the elexacaftor–tezacaftor–ivacaftor group at week 24 was 57.9 mmol per liter, as compared with 102.4 mmol per liter in the placebo group (Fig. S5).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Elexacaftor–Tezacaftor–Ivacaftor (N = 200)</th>
<th>Placebo (N = 203)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female sex — no. (%)</td>
<td>96 (48.0)</td>
<td>98 (48.3)</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean — yr</td>
<td>25.6±9.7</td>
<td>26.8±11.3</td>
</tr>
<tr>
<td>Distribution — no. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 to &lt;18 yr</td>
<td>56 (28.0)</td>
<td>60 (29.6)</td>
</tr>
<tr>
<td>≥18 yr</td>
<td>144 (72.0)</td>
<td>143 (70.4)</td>
</tr>
<tr>
<td>Geographic region — no. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>North America</td>
<td>118 (59.0)</td>
<td>120 (59.1)</td>
</tr>
<tr>
<td>Europe or Australia</td>
<td>82 (41.0)</td>
<td>83 (40.9)</td>
</tr>
<tr>
<td>Percentage of predicted FEV₁</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>61.6±15.0</td>
<td>61.3±15.5</td>
</tr>
<tr>
<td>Distribution — no. (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;40%</td>
<td>18 (9.0)</td>
<td>16 (7.9)</td>
</tr>
<tr>
<td>40 to &lt;70%</td>
<td>114 (57.0)</td>
<td>120 (59.1)</td>
</tr>
<tr>
<td>70 to ≤90%</td>
<td>66 (33.0)</td>
<td>62 (30.5)</td>
</tr>
<tr>
<td>&gt;90%</td>
<td>2 (1.0)</td>
<td>5 (2.5)</td>
</tr>
<tr>
<td>Body-mass index</td>
<td>21.49±3.07</td>
<td>21.31±3.14</td>
</tr>
<tr>
<td>Sweat chloride concentration — mmol/liter</td>
<td>102.3±11.9</td>
<td>102.9±9.8</td>
</tr>
<tr>
<td>CFQ-R respiratory domain score§</td>
<td>68.3±16.9</td>
<td>70.0±17.8</td>
</tr>
</tbody>
</table>

* Plus–minus values are means ±SD. FEV₁ denotes forced expiratory volume in 1 second.
† Age distribution was calculated on the basis of age at the time of screening.
‡ Although those eligible for enrollment were required to have a percentage of predicted FEV₁ of 40% or more at screening, some participants had a decrease to a value of less than 40% by baseline.
§ Scores on the Cystic Fibrosis Questionnaire—Revised (CFQ-R) are normalized to range from 0 to 100, with higher scores indicating a higher patient-reported quality of life with regard to respiratory symptoms.
The CFQ-R respiratory domain score improved significantly through week 24 in the elexacaftor–tezacaftor–ivacaftor group, with a mean treatment difference of 20.2 points relative to placebo (P<0.001) (Table 2 and Fig. 2C). BMI also improved significantly at week 24, with a mean treatment difference of 1.04 relative to placebo (P<0.001) (Table 2 and Fig. S6). All additional secondary efficacy end points showed improvement (Table 2 and Table S5).

### SAFETY

Table 3 provides an overview of adverse events. The percentage of patients with at least one adverse event was 93.1% in the elexacaftor–tezacaftor–ivacaftor group and 96.0% in the placebo group; excluding adverse events of pulmonary exacerbation, the percentage was 92.6% in the elexacaftor–tezacaftor–ivacaftor group and 93.0% in the placebo group. Adverse events occurring in at least 10% of patients in either trial group were consistent with common manifestations and complications of cystic fibrosis. The majority of patients in the elexacaftor–tezacaftor–ivacaftor group had adverse events that were mild (33.2%) or moderate (50.5%) in severity. The large majority of adverse events resolved during the trial.

Serious adverse events occurred in 28 patients (13.9%) in the elexacaftor–tezacaftor–ivacaftor group and 42 patients (20.9%) in the placebo group (Table 3 and Table S6); excluding serious adverse events of pulmonary exacerbation, serious adverse events occurred in 20 patients (9.9%) in the elexacaftor–tezacaftor–ivacaftor group and 16 patients (8.0%) in the placebo group. There were no deaths in either trial group. Two patients (1.0%) in the elexacaftor–tezacaftor–ivacaftor group discontinued the trial regimen because of adverse events: rash in 1 patient and portal hypertension in a patient with preexisting cirrhosis.
No patients in the placebo group discontinued the trial regimen because of an adverse event.

On the basis of previous experience with CFTR modulator therapy,9-12 including the phase 2 trial of elexacaftor–tezacaftor–ivacaftor,18 data related to aminotransferase levels and rash were reviewed. Adverse events of elevated aminotransferase levels occurred in 22 patients (10.9%) in the elexacaftor–tezacaftor–ivacaftor group and 8 patients (4.0%) in the placebo group. In the elexacaftor–tezacaftor–ivacaftor group, elevated levels of alanine aminotransferase or aspartate aminotransferase that were greater than three times, greater than five times, and greater than eight times the upper limit of the normal range occurred in 16 patients (7.9%), 5 patients (2.5%), and 3 patients (1.5%), respectively, as compared with 11 patients (5.5%), 3 patients (1.5%), and 2 patients (1.0%) in the placebo group. No patient had an elevated aminotransferase level greater

---

**Figure 1. Absolute Change from Baseline in Percentage of Predicted FEV₁, and Rate of Pulmonary Exacerbations.**
Panel A shows the absolute change from baseline in percentage of predicted forced expiratory volume in 1 second (FEV₁), based on a mixed-effects model for repeated measures. Data are least-squares means, and I bars indicate standard error of the mean; the dashed line indicates no change from baseline. Panel B shows a histogram of absolute change from baseline in percentage of predicted FEV₁ through week 24, according to trial group. Panel C shows the overall estimated annualized rate of pulmonary exacerbations, the estimated annualized rate of pulmonary exacerbations leading to hospitalization, and the estimated annualized rate of pulmonary exacerbations treated with intravenous antibiotics. CI denotes confidence interval.
than three times the upper limit of the normal range concurrent with an elevated bilirubin level greater than two times the upper limit of the normal range that emerged during the intervention period. Rash occurred in 22 patients (10.9%) in the elexacaftor–tezacaftor–ivacaftor group and 13 patients (6.5%) in the placebo group. In both trial groups, rash was more common in female patients than in male patients and more common in female patients who used hormonal contraceptives than in those who did not (Table S7).

Additional observations included elevated levels of creatine kinase and blood-pressure changes in the elexacaftor–tezacaftor–ivacaftor group. Elevated levels of creatine kinase were often associated with exercise, and no elevations of creatine kinase led to discontinuation of the trial regimen (Table S8). The baseline mean systolic and diastolic blood pressures in the elexacaftor–tezacaftor–ivacaftor group were 113.4 mm Hg and 69.4 mm Hg, and they increased by 3.1 mm Hg and 1.9 mm Hg, respectively, at week 24 (Table S9). There were no relevant safety findings in other clinical or laboratory assessments.

Figure 2. Absolute Change from Baseline in Sweat Chloride Concentration and CFQ-R Respiratory Domain Score.
Panel A shows the absolute change from baseline in sweat chloride concentration, based on a mixed-effects model for repeated measures; a reduction over time indicates improvement in CFTR function. Panel B shows a histogram of absolute change from baseline in sweat chloride concentration through week 24, according to trial group. Panel C shows the absolute change from baseline in the respiratory domain score on the Cystic Fibrosis Questionnaire–Revised (CFQ-R), based on a mixed-effects model for repeated measures. Scores are normalized to range from 0 to 100 points, with higher scores indicating a higher patient-reported quality of life with regard to respiratory symptoms; the minimum clinically important difference is 4 points. In Panels A and C, least-squares means at each visit are shown, and the I bars indicate the corresponding standard error; the dashed line indicates no change from baseline.
In this 24-week trial of triple-combination CFTR modulator therapy in patients with cystic fibrosis who have a single Phe508del allele, elexacaftor–tezacaftor–ivacaftor treatment resulted in improvements in lung function, the rate of pulmonary exacerbations, sweat chloride concentration, CFQ-R respiratory domain scores, and BMI and was generally safe with an acceptable side-effect profile, findings that are consistent with those of the phase 2 trial of elexacaftor–tezacaftor–ivacaftor. The efficacy outcomes confirm the hypothesis that elexacaftor–tezacaftor–ivacaftor effectively modulates the function of Phe508del CFTR from a single allele, providing pronounced benefits in a population of patients in whom previous CFTR modulator therapies were not effective.

Elexacaftor–tezacaftor–ivacaftor therapy improved multiple outcome measures. FEV₁ is a strong predictor of clinical status in cystic fibrosis, and elexacaftor–tezacaftor–ivacaftor resulted in sustained improvements in this end point. Pulmonary exacerbations are important clinical events associated with disease progression; elexacaftor–tezacaftor–ivacaftor resulted in a lower rate of pulmonary exacerbations, including severe events leading to hospitalization or treatment with intravenous antibiotics, than placebo. Improvements in respiratory symptoms and in systemic indicators of clinical benefit, including nutritional outcomes, were also noted.

The current benchmark for highly effective CFTR modulator therapy is ivacaftor for patients with the Gly551Asp CFTR mutation, in whom disease modification has been shown with long-term use, including decreased lung-function decline and decreased mortality. The improvement in the primary end point of absolute change in percentage of predicted FEV₁ was 10.6 points in patients with the Gly551Asp allele. In the present trial of elexacaftor–tezacaftor–ivacaftor in patients with a single Phe508del allele, the improvement in percentage of predicted FEV₁ was 13.8 points, relative to placebo. Furthermore, the mean sweat chloride concentration in patients with a single Phe508del allele who received elexacaftor–tezacaftor–ivacaftor for 24 weeks decreased from 102 mmol per liter to 58 mmol per liter, just below the generally accepted diagnostic threshold for cystic fibrosis (≥60 mmol per liter); this finding reflects improved CFTR function.

Ivacaftor and tezacaftor–ivacaftor, two components of this triple combination, are approved therapies, with well-characterized safety profiles. Similar to these agents, elexacaftor–tezacaftor–ivacaftor therapy was associated with adverse events that were mostly mild to moderate, that generally represented common manifestations of cystic fibrosis, and that led to few treatment discontinuations. An increase in the incidence of elevated aminotransferase levels, which occur sporadically in many persons with
cystic fibrosis, was observed with elexacaftor–tezacaftor–ivacaftor treatment; these adverse events were low grade (i.e., mild or moderate) in 20 of 22 patients (91%) and were not treatment-limiting. In general, cases of rash were mild to moderate and did not lead to alteration of treatment administration. The elevated serum levels of creatine kinase that were observed were generally asymptomatic and often associated with exercise. The modest increase in mean blood pressure that was observed with elexacaftor–tezacaftor–ivacaftor may be related to salt preservation, improved nutritional status, or other effects of CFTR modulation; evaluation of blood pressure in patients who begin to receive treatment may help to clarify the clinical relevance of this observation.

Unlike previous CFTR modulators, triple-combination therapy with elexacaftor–tezacaftor–ivacaftor strongly modulates CFTR in persons with Phe508del–minimal function genotypes. The effect on Phe508del CFTR was evident in the 78% of patients with minimal-function mutations that are associated with an absence of CFTR protein production, who had a response to elexacaftor–tezacaftor–ivacaftor that could occur only through modulation of Phe508del CFTR. These data support the hypothesis that the presence of a single Phe508del allele is sufficient to impart the benefit of triple-combination therapy independent of the minimal-function mutation.

The restoration of Phe508del CFTR by elexacaftor–tezacaftor–ivacaftor was further confirmed by a concurrent phase 3 trial involving patients with two Phe508del alleles, which showed substantially improved outcomes, including increased lung function and decreased patient-reported respiratory symptoms, as compared with the dual combination of tezacaftor–ivacaftor. Further research to extend the benefit of CFTR modulation to patients with responsive mutations other than the Phe508del CFTR mutation is imperative.

In conclusion, this 24-week, phase 3 trial involving 403 patients with cystic fibrosis confirmed the efficacy of triple-combination CFTR modulator therapy in patients 12 years of age or older who were heterozygous for the Phe508del CFTR mutation and a minimal-function mutation. No worrisome safety signals were noted. These results provide evidence that elexacaftor–tezacaftor–ivacaftor can modulate a single Phe508del allele in people with cystic fibrosis, thus addressing the underlying cause of disease in the large majority of patients.

Supported by Vertex Pharmaceuticals. The National Institutes of Health provided grant support to the University of Alabama at Birmingham (P30DK072482, R35HL135816, and U54TR001368) and Seattle Children's Hospital (P30-DK-089507, SU1 TR 0002319, and IU01TR 002487).

Dr. Middleton reports receiving advisory board fees, research funding, and clinical-trial support, paid to his institution, from Vertex Pharmaceuticals and clinical-trial support from Proteostasis Therapeutics and Galapagos; Dr. Mall, receiving consulting fees, lecture fees, and travel support from Bayer, advisory board fees, consulting fees, editorial board fees, and travel support from Boehringer Ingelheim, advisory board fees, consulting fees, and travel support from Polyphor, advisory board fees and consulting fees from Arrowhead Pharmaceuticals, ProQR Therapeutics, Spyryx Biosciences, Santhera Pharmaceuticals, and Enterprise Therapeutics, grant support, advisory board fees, lecture fees, and travel support from Vertex Pharmaceuticals, consulting fees from Galapagos and Stenna Biologics, and lecture fees from Celtsys; Dr. Dřevínek, receiving fees for serving on a clinical trial and consulting fees from Vertex Pharmaceuticals, fees for serving on a clinical trial from Galapagos, Flatley Discovery Lab, and Corbus Pharmaceuticals, and consulting fees from Proteostasis Therapeutics, Actelion Pharmaceuticals, and Chiesi; Dr. Lands, receiving advisory board fees from Proteostasis Therapeutics, serving as chief medical advisor and co-principal investigator of a trial for Laurent Pharmaceuticals, advisory board fees and fees for preparation of educational material from Vertex Pharmaceuticals, and holding patents #60/750,004, #12/097,229, and #14/172,954 on a method for correcting a lipid imbalance in a subject; Dr. McKone, receiving advisory board fees from Proteostasis Therapeutics, grant support from Gilead Sciences, travel support from Novartis, and grant support, advisory board fees, and lecture fees from Vertex Pharmaceuticals; Dr. Polimeni, receiving grant support, advisory board fees, and travel support from Vertex Pharmaceuticals and grant support from Proteostasis Therapeutics, Parion Sciences, and Laurence Pharmaceuticals; Dr. Taylor-Cousar, receiving advisory board fees and lecture fees from Gilead Sciences, grant support, paid to her institution, consulting fees, and lecture fees from Proteostasis Therapeutics and Celtsys, advisory board fees from Protalix Biotherapeutics, consulting fees from Santhera Pharmaceuticals, and grant support, paid to her institution, consulting fees, advisory board fees, and lecture fees from Vertex Pharmaceuticals; Dr. Tallis, receiving grant support, consulting fees, and travel support from Proteostasis Therapeutics, grant support from AbbVie, and grant support, honoraria, consulting fees, and travel support from Vertex Pharmaceuticals; Drs. Marigowda and McKee, being employed by and owning stock in Vertex Pharmaceuticals; Dr. Moskovitz, being employed by and holding stock options in Vertex Pharmaceuticals and holding pending patent PCT/US2018/042486 on methods of treatment for cystic fibrosis and pending patent PCT/US2019/016537 on pharmaceutical compositions for treating cystic fibrosis; Drs. Nair, Savage, Simard, and Tian, being employed by and owning stock in Vertex Pharmaceuticals; Dr. Waltz, being employed by and holding stock options in Vertex Pharmaceuticals and holding pending patent PCT/US2018/042486 on methods of treatment for cystic fibrosis and pending patent PCT/US2019/016537 on pharmaceutical compositions for treating cystic fibrosis; Dr. Xuan, being employed by and holding stock options in Vertex Pharmaceuticals; Dr. Rowe, receiving grant support from Forest Research Institute, AstraZeneca, N30 Pharmaceuticals/Nivalis Therapeutics, Galapagos/
A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. We thank the patients and their families for participating in this trial and the trial investigators and coordinators for their contributions to the trial; Sarah Garber, Pharm.D., former employee of Vertex Pharmaceuticals, and Swati Thorat, Ph.D., employee of Vertex Pharmaceuticals, who may own stock or stock options in the company, for providing editorial coordination and support; and Karla Kaluza Smith, Ph.D., C.M.P.P., of ArticulateScience for providing editorial assistance under the guidance of the authors and with support from Vertex Pharmaceuticals.

---

**APPENDIX**

The authors’ full names and academic degrees are as follows: Peter G. Middleton, M.D., Marcus A. Mall, M.D., Pavel Dřevínek, M.D., Larry C. Lands, M.D., Edward F. McKone, M.D., Deepika Polinec, M.D., Bonnie W. Ramsey, M.D., Jennifer L. Taylor-Cousar, M.D., Elizabeth Tullis, M.D., François Vermeulen, M.D., Gautham Marigowda, M.D., Charlotte M. McKee, M.D., Samuel M. Moskowitz, M.D., Nitin Nair, Ph.D., Jessica Savage, M.D., Christopher Simard, M.D., Simon Tian, M.D., David Waltz, M.D., Fengjuan Xuan, Ph.D., Steven M. Rowe, M.D., and Raksha Jain, M.D. The authors’ affiliations are as follows: the Department of Respiratory and Sleep Medicine, Westmead Hospital and CF Research Group, Ludwig Engel Centre for Respiratory Research, Westmead Institute for Medical Research, University of Sydney, Westmead, NSW, Australia (P.G.M.); the Department of Pediatric Pulmonology, Immunology, and Intensive Care Medicine, Charité–Universitätsmedizin Berlin, the Berlin Institute of Health, and the German Center for Lung Research, Berlin (M.A.M.); the Department of Medical Microbiology, Department of Pediatrics, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic (P.D.); the Pediatric Respiratory Medicine and Pediatric Cystic Fibrosis Clinic, Lausanne University Health Centre, Montreal (L.C.L.); St. Vincent’s University Hospital and University College Dublin School of Medicine, Dublin (E.F.M.); the Department of Internal Medicine, University of Kansas Medical Center, Kansas City (D.P.); the Department of Pediatrics, University of Washington School of Medicine, and Seattle Children’s Research Institute, Seattle (B.W.R.); the Departments of Medicine and Pediatrics, National Jewish Health, Denver (L.J.T.-C.); the Division of Respirology, St. Michael’s Hospital, University of Toronto, Toronto (E.T.); the Cystic Fibrosis Reference Center, Department of Pediatrics, Catholic University of Leuven, Leuven, Belgium (F.V.); Vertex Pharmaceuticals, Boston (G.M., C.M.M., S.M.M., N.J., C.S., S.T., D.W., F.X.); the Departments of Medicine, Pediatrics, and Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham (S.M.R.); and the Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas (R.J.).

---

**REFERENCES**

Primary exacerbations is associated with poor long-term outcomes. Pediatr Pulmonol 2017;52:1268-75.


